Hi
It's a small step that's taken years in planning and persistence in gaining regulatory approvals for take home use and we are pleased to announce the first dose has been administered.
It's a Phase 2B microdosing trial in patients with Major Depressive Disorder, dosing with MB22001, a proprietary titratable self-administered form of Lysergic Acid Diethylamide (LSD) designed for take home use.
In this Phase 2B trial, a randomised, triple blind and active placebo controlled trial (n=90), half of the patients will be given MB22001 and half will be given an active placebo over an 8 week trial. At the end of the 8 weeks, all clinical trial participants will be offered an open label extension of 8 weeks on MB22001 to give patients in the placebo group the opportunity to be treated with the drug.
It's a great next step in developing this new promising treatment for depression and other related conditions.
We thank you for your support and interest in our scientific work.
Click on the link to view a brief slideshow.
Stay Well!
JUSTIN HANKA
Chief Executive Officer & Co-Founder
MindBio Therapeutics Corp (Frankfurt: WF6), (CNSX: MBIO)
Follow CEO Justin Hanka on LinkedIn:
https://www.linkedin.com/in/justinhanka/
Follow MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true
0 comments